# Human IgG1 Constant Region Sequences
#
# Standard sequences for assembling full-length antibodies and bispecifics.
# All sequences are human IgG1 with optional Fc-silencing mutations.
#
# Numbering: EU numbering system
# Source: UniProt P01857 (IGHG1_HUMAN)

# Light chain constant regions
kappa_cl:
  name: Human Kappa CL
  sequence: >-
    RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
    LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  length: 107
  source: UniProt P01834

lambda_cl:
  name: Human Lambda CL
  sequence: >-
    GQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYA
    ASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS
  length: 106
  source: UniProt P0CG04

# Heavy chain constant regions
ch1:
  name: Human IgG1 CH1
  sequence: >-
    ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS
    VVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
  length: 98
  source: UniProt P01857

hinge:
  name: Human IgG1 Hinge
  sequence: EPKSCDKTHTCPPCP
  length: 15
  notes: Contains two disulfide bonds between heavy chains
  source: UniProt P01857

# IgG1 hinge variants
hinge_variants:
  standard:
    sequence: EPKSCDKTHTCPPCP
    notes: Wild-type IgG1 hinge

  igg4_like:
    sequence: ESKYGPPCPPCP
    notes: IgG4-like hinge, reduced Fab arm exchange
    use_case: When IgG4-like properties desired

ch2:
  name: Human IgG1 CH2
  sequence: >-
    APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
    STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
  length: 110
  source: UniProt P01857

ch3:
  name: Human IgG1 CH3
  sequence: >-
    GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
    SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  length: 107
  source: UniProt P01857

# Complete Fc region (hinge + CH2 + CH3)
fc_wild_type:
  name: Human IgG1 Fc (wild-type)
  sequence: >-
    EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
    EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
    TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
    WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  components:
    - hinge
    - ch2
    - ch3
  notes: Includes full effector function (ADCC, CDC)

# Fc-silenced variant (LALA mutation)
fc_lala:
  name: Human IgG1 Fc (LALA - Fc-silenced)
  sequence: >-
    EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
    EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
    TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
    WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  mutations:
    - position: 234
      from: L
      to: A
      effect: Reduces FcγRI binding
    - position: 235
      from: L
      to: A
      effect: Reduces FcγRII/III binding
  notes: >-
    Standard Fc-silencing for bispecifics where effector function
    is not desired. Reduces ADCC and CDC.
  use_case: T-cell engaging bispecifics

# Fc-silenced variant (LALAPG - enhanced silencing)
fc_lalapg:
  name: Human IgG1 Fc (LALA-PG - enhanced Fc-silenced)
  sequence: >-
    EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV
    EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVY
    TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
    WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  mutations:
    - position: 234
      from: L
      to: A
    - position: 235
      from: L
      to: A
    - position: 329
      from: P
      to: G
      effect: Further reduces C1q binding (CDC)
  notes: Enhanced silencing including reduced CDC
  use_case: When complete effector silencing required
